Conference on Retroviruses and Opportunistic Infections

Conference on Retroviruses and Opportunistic Infections
Name	Conference on Retroviruses and Opportunistic Infections
Abbreviation	CROI
Status	Active
Frequency	Annual
Venue	Varies
First	1993
Organizer	International Antiviral Society–USA

Conference on Retroviruses and Opportunistic Infections is an annual scientific meeting focused on HIV/AIDS, retrovirus research, and related opportunistic infection studies. The meeting gathers researchers, clinicians, public health officials, and industry representatives from institutions such as National Institutes of Health, Centers for Disease Control and Prevention, World Health Organization, Johns Hopkins University, and University of California, San Francisco. Presentations frequently influence policy at organizations including United Nations, Pew Charitable Trusts, Bill & Melinda Gates Foundation, and European Commission.

Overview

The conference serves as a forum for basic science, clinical trials, epidemiology, and implementation research, attracting delegates from Harvard University, Massachusetts General Hospital, Stanford University, University of Oxford, Imperial College London, Columbia University, Weill Cornell Medicine, University of Toronto, Karolinska Institutet, and University of Cape Town. Topics integrate work from laboratories associated with Cold Spring Harbor Laboratory, Broad Institute, Salk Institute, Ragon Institute, and La Jolla Institute for Immunology. Key stakeholders include representatives from Gilead Sciences, ViiV Healthcare, AbbVie, GlaxoSmithKline, Pfizer, and Merck & Co..

History and Development

Founded in the early 1990s, the meeting emerged amid global efforts led by entities such as United Nations Programme on HIV/AIDS, World Health Assembly, Global Fund to Fight AIDS, Tuberculosis and Malaria, and Clinton Foundation initiatives. Early conferences featured investigators from National Institute of Allergy and Infectious Diseases, Fred Hutchinson Cancer Research Center, Seattle Biomedical Research Institute, Mayo Clinic, Dana-Farber Cancer Institute, and Scripps Research. Over decades, the program expanded alongside milestones from International AIDS Conference, Ryan White CARE Act, Montreal Protocol-era biomedical policy shifts, and pivotal trials coordinated by networks like INSIGHT, HIV Prevention Trials Network, and International Maternal Pediatric Adolescent AIDS Clinical Trials Network.

Scientific Program and Topics

Sessions span virology, immunology, antiretroviral therapy, prevention, and coinfection, featuring investigators from National Cancer Institute, European AIDS Clinical Society, American Academy of HIV Medicine, Infectious Diseases Society of America, and Pediatric Infectious Diseases Society. Topics include pathogen biology explored at Max Planck Institute for Infection Biology, drug development highlighted by Food and Drug Administration approvals, vaccine research linked to Moderna, Pfizer–BioNTech, and AstraZeneca, and implementation science involving Clinton Health Access Initiative, Partners In Health, and Médecins Sans Frontières. Sessions also cover tuberculosis intersections with HIV presented by teams from Stop TB Partnership, KNCV Tuberculosis Foundation, and Public Health England.

Notable Presentations and Findings

Historic presentations have included pivotal antiretroviral trial results from investigators affiliated with Harvard Medical School, University of Washington, Yale School of Medicine, University College London, and Monash University. Landmark findings announced at the meeting have influenced guidelines from World Health Organization, European Medicines Agency, U.S. Department of Health and Human Services, and Public Health Agency of Canada. Major translational reports have come from collaborations with Bill & Melinda Gates Foundation-funded programs, Wellcome Trust consortia, and networks such as International AIDS Vaccine Initiative and Family Health International. High-impact abstracts have shaped strategies promoted by President's Emergency Plan for AIDS Relief, UNAIDS, and Global Fund distributions.

Organizational Structure and Sponsorship

The conference is organized by a steering committee composed of academic leaders from University of California, San Diego, Yale University, McGill University, University of Barcelona, and University of São Paulo, with advisory input from representatives of National Institutes of Health, Centers for Disease Control and Prevention, and international bodies like Pan American Health Organization. Sponsorship blends support from pharmaceutical companies such as Gilead Sciences, ViiV Healthcare, Merck & Co., and philanthropic funders including Bill & Melinda Gates Foundation, Wellcome Trust, and Robert Wood Johnson Foundation. Organizational governance aligns with standards of International Committee of Medical Journal Editors and disclosure frameworks used by journals like The Lancet, New England Journal of Medicine, and Journal of the American Medical Association.

Attendance, Impact, and Media Coverage

Attendance typically includes investigators from European Society for Clinical Virology, African Society for Laboratory Medicine, Asia Pacific AIDS & Co-infections Conference affiliates, and representatives from ministries such as Ministry of Health (Brazil), South African Department of Health, and Indian Council of Medical Research. Media coverage has been provided by outlets like The New York Times, BBC News, The Guardian, Science (journal), Nature (journal), and The Washington Post, while analysis appears in specialist sources such as AIDSmap, STAT News, and MedPage Today. The conference's influence extends to policy shifts at United States Congress hearings, guideline revisions by World Health Organization, and funding priorities by National Institutes of Health and European Commission Horizon Europe programs.

Category:HIV/AIDS conferences